BILLERICA, Mass.--(BUSINESS WIRE)--Feb. 28, 2018--
Insulet Corporation (NASDAQ:PODD) (Insulet), the leader in tubeless
insulin pump technology with its Omnipod® Insulin
Management System, today announced that management will present at three
upcoming investor conferences:
This press release features multimedia. View the full release here:
The Raymond James & Associates’ 39th Annual Institutional Investors
Conference in Orlando, Florida on Monday, March 5, 2018 at 11:00 a.m.
- The Cowen and Company 38th Annual Health Care Conference in Boston,
Massachusetts on Monday, March 12, 2018 at 12:00 p.m. (Eastern Time).
- The Barclays Global Healthcare Conference in Miami, Florida on
Tuesday, March 13, 2018 at 9:30 a.m. (Eastern Time).
To listen to live audio webcasts of the presentations, please visit http://investors.insulet.com.
Replays of the webcasts will also be available following the events.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is
an innovative medical device company dedicated to making the lives of
people with diabetes and other conditions easier through the use of its
Omnipod product platform. The Omnipod Insulin Management System provides
a unique alternative to traditional insulin delivery methods. With its
simple, wearable design, the disposable Pod provides up to three days of
non-stop insulin delivery, without the need to see or handle a needle.
Insulet also leverages the unique design of its Pod, by tailoring its
Omnipod technology platform for the delivery of non-insulin subcutaneous
drugs across multiple therapeutic areas. Founded in 2000, more than
140,000 users across the globe rely on Insulet’s Omnipod Insulin
Management System to bring simplicity and freedom to their lives. For
more information, please visit: www.insulet.com,
*Starting July 1, 2018, Insulet will assume direct distribution of its
Omnipod Insulin Management System in Europe, including sales, marketing,
training and customer support activities. This will allow Insulet to be
closer to the diabetes community and identify opportunities to support
European customer needs over the long-term, as it already does in the
United States and Canada.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180228005710/en/
Source: Insulet Corporation
Investor Relations and Media Contact:
Vice President, Investor Relations and